Study	Reason for exclusion
Balocco 1992	Letter to editor reporting on the results of pregnancy of 24 women exposed to mefloquine in early pregnancy. The report was excluded because it did not meet the inclusion criteria.
Briand 2015	This publication reports the findings of a re‐analysis of previous published data comparing mefloquine with sulphadoxine‐pyrimethamine for IPTp in Benin using a multiple outcome approach, which allowed the joint assessment of efficacy and tolerability. This analysis was not included in the review because the original study (Briand 2009 BEN) was already included and it did not add additional data.
Denoeud‐Ndam 2012	Study comparing mefloquine tolerability as IPTp between HIV‐infected and uninfected women participating in three included trials from Benin (Briand 2009 BEN and Denoeud‐Ndam 2014a and b). This analysis was excluded from the review because it did not provide additional data from already included trials.
Nosten 1990 THA	The study was designed as a dose‐finding pharmacokinetic study in 20 pregnant women in the third trimester of pregnancy who received mefloquine as prophylaxis. The trial did not compare the safety and efficacy of mefloquine with another antimalarial drug and thus, it did not meet inclusion criteria.
Phillips‐Howard 1998	Publication reporting on a data analysis of reported use of mefloquine during the 1st trimester of pregnancy in European travellers. This analysis was excluded from the review because it did not meet inclusion criteria.
Schlagenhauf 2012	This publication presents the analysis of the reports of exposure to mefloquine in pregnancy received by the Roche post‐marketing surveillance system. This analysis was excluded from the review because it did not meet inclusion criteria.
Smoak 1997	This publication reports a case series of 72 US soldiers who inadvertently took mefloquine during pregnancy for prophylaxis. This publication was excluded from the review because it did not meet inclusion criteria.
Steketee 1996 MAL	We were not convinced that allocation was unbiased. Quote: "The assignment of regimens was based on the clinic day of enrolment. All women making their first antenatal clinic visit on a given day were assigned to the same regimen; the following clinic day, enrolled women were assigned a different regimen". We noted bias in allocation supported by statistically and clinically significant differences between intervention groups (3 groups under different chloroquine regimens versus 1 group under mefloquine regimen).
Vanhauwere 1998	Study evaluating 1627 reports of mefloquine exposure pregnancy, mainly for chemoprophylaxis received by the Roche Post‐marketing surveillance system between 1986 and 1996.This analysis was excluded from the review because it did not meet inclusion criteria.